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ABSTRACT
Background: Diabetic foot ulcers (DFUs) are one of the major complications of poorly
controlled diabetes. The DFUs result due to the damage and breaking of the skin beneath it.
The most commonly affected locations of DFUs are the extreme proximities of the toes. The
wounds associated with foot ulcerations are the leading causes of the leg amputation.
Metformin, a widely used anti- diabetic agent has a vital role in AMPK activation as well as
plays an inhibitory effect on the mTOR, and Cyclin D1 pathways. Thereby causing a delay in
the usual process of healing of wound in the patients. Therefore, purpose of the study was
understanding metformin effect on wound healing in DFU patients.
Objectives: The primary study objective was to determine metformin effect on wound healing
in DFU patients. Secondary objective was to assess the health-related quality of life (HRQOL)
and investigate general prescribing practices for the management of DFU.

Methods: A prospective cohort study was carried out for a period of 7 months (August 2019
to February 2020). A total of 76 patients with old and new diabetic foot infections and
gangrene were recruited based on the inclusion and exclusion criteria. Patients were selected
into two cohorts: DFU patients receiving metformin and its combinations were considered as
study cohort and patients receiving any other anti-diabetic drug therapy were considered
reference cohort. These patients’ wound diameters, sugar profile and healing time were
monitored with a follow up after 4 months. All the patients were provided with a quality of
life (QoL) tool - diabetic foot ulcer scale- Short form questionnaire (DFS-SF). Additionally,
the prescription patterns of the DFU patients were also evaluated. IBM (SPSS) version.25.0
was used for statistical analysis and p <0.05 was considered as statistically significant.
Results: A statistically significant association was found between delay in wound healing and
metformin use (X2= 4.846; p = 0.028). Similarly, a statistically significant association was
found with amputations and metformin use (X2= 4.31, p = 0.038). QoL scores between male
and female showed that men had better mean scores in domains of health (61.3 ± 3.30),
dependency (56.7 ± 3.54) and bothered by ulcers (61.9 ± 2.87). Whereas, women had better
mean scores in the physical domains of leisure (67.5 ± 7.78), daily life (69.8 ± 8.52) and
psychological domains of negative emotions (48.6 ± 6.57) and worried by ulcers (61.5 ± 7.17).
72.7% of the study cohort patients received insulin, whereas 100% of the reference cohort
patients received insulin. The penicillin was the commonly prescribed antibiotic class in study
cohort (52.3%) and reference cohort (71.8%).
Conclusion: Study shows a significant delay in the process of healing of wound in DFU
patients on metformin compared to patients on other anti-diabetic therapy. Most importantly,
a higher incidence of lower extremity amputations was seen in metformin group compared to
another anti-diabetic agent group. The prescribing patterns of the drugs showed that insulin
was the most commonly antidiabetics, whereas penicillin was the most commonly prescribed
antibiotics in DFU patients.

INTRODUCTION

INTRODUCTION
Diabetes is a metabolic syndrome which affects the metabolism of protein, fat and
carbohydrates. It affects the glucose metabolism by decreasing the insulin sensitivity and
glucose uptake into the cells. It is characterized by high sugar levels for a prolonged period of
time. The syndrome is further classified as type 1 diabetes (T1DM) and type 2 diabetes
(T2DM).
Diabetes often has tendency to progress into either acute complication like diabetic
ketoacidosis, hyperosmolar hyperglycaemic conditions or serious long- term ones like
cardiovascular diseases, stroke, chronic kidney diseases, eye complications and foot ulcers.
Worldwide, in the current scenario, diabetic foot related problems are the major aetiology for
nontraumatic lower extremities amputations in the world. Leg and foot ulcers are the most
common wounds in them. Diabetic patients especially with diabetic foot ulcers (DFUs) are
highly susceptible to wounds, small wound can result into major complications in these
patients. An unhealed ulcer can further advance to development of gangrene, which may lead
to leg amputations. The risk of having amputations of the lower extremities ranges from 15 to
46 times more in patients with diabetes than non-diabetes.
In India, DFUs affect around 15% of the population having diabetes during their life
expectancy. Diabetic foot infections (DFIs) are either mono or polymicrobial in growth and
seen high prevalence of infections with Pseudomonas, Escherichia coli (E. coli), and
Staphylococcus aureus (S. aureus). Evidences shows 0.1 million lower limb amputations per
year because of diabetic foot complications. (1)
The inability to metabolize the glucose results in hyperglycaemia state which complicates the
wound healing process by decreasing the availability of nutrients and oxygen to reach the
tissues, thereby decreasing the functionality of the immune system efficiently

(2).

Altered

carbohydrate and protein metabolism causes abnormal granulation tissue formation, altered
metabolism of nitric oxide (NO), which are known to be important for cell proliferation,
maturation. Synthesis of differentiation stimulator is decreased in the patients due to decreased
ability to generate NO from l- arginine due to accumulation of NO synthetase inhibitor. As a
response to high glucose associated kidney dysfunction causes decreased tensile strength and
cross linking of collagen near the wound, also decreases the angiogenesis process

(3)

. Matrix

metalloproteins also degrade the extracellular matrix components, which are involved in
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fibrinoblasts and keratinocyte migration, hence affecting the reorganisation, remodelling and
healing of the wounded tissue (4).
Metformin, is an anti-diabetic medication belongs to the class of biguanide, which is
extensively used in the management of T2DM as it exhibits a clear benefit in relation to glucose
metabolism and diabetes- related complications

(5)

. In addition to the prior mechanisms of

wound healing delay of diabetes, patients on biguanide therapy like metformin have a delay in
the healing process by a different mechanism. Various epidemiological research conducted in
patients with diabetes exhibited metformin have a protective effect against the development of
various kind of cancer. The mechanism underlining this protective effect is related to the action
of metformin on proliferation of cell. Amon these, mammalian target of rapamycin (mTOR),
adenosine mono phosphate-activated protein kinase (AMPK) as well as other targets like cyclin
D1 pathway have been identified (6).
The mTOR pathway is essential for cell growth, which is one of the major mechanisms for
cancer induction in the mammalian cells. Moreover, it is essential for tumour cell growth,
proliferation and survival. The AMPK is an important energy-sensing enzyme which helps in
maintenance of the cellular energy homeostasis. It is seen that activation of AMPK has reversal
and negative effects on the mTOR pathway. The tuberous sclerosis complex 2 (TSC2) gets
direct phosphorylation and activation by activated AMPK. This attributes to mTOR1 signalling
pathway inhibition, which is essential for cell growth, proliferation and survival (7).
Metformin is known to activate the AMPK cascade by stimulating the phosphorylation of
AMPK. This is a downstream component of protein kinase cascade acting as a sensor of cellular
energy charge. This decrease the glucose production in liver and increase the glucose uptake
by the peripheral muscles by the translocation of GLUT 4 vesicle and increases the glycolysis
rate. This in turn exhibits a reversal effects on mTOR signalling pathway, by inactivation of
mTOR which results in decreased protein synthesis and cell proliferation, which delays the
process of healing and causes improper wound closure (8).
Appropriate healing of any mucosal wound needs a proper orchestration of epithelial migration
as well as proliferation, which is the key mechanism. This needs proper expression of cell cycle
regulators especially in the G1 phase progression and S phase entry (9.) Metformin also affects
this pathway by inducing the G1 cell cycle arrest, in parallel to degradation of the cyclin D1
protein expression without affecting the transcription process via AMPK/ GSK 3β signalling
thereby decreasing the cell proliferation (10). However, there is paucity of the knowledge on the
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role of metformin on other types of cell like keratinocytes. It is not sure whether exposure to
the drug on the above cells might have severe consequences like delay in healing of wound as
well as development of foot ulcer complications in patients with diabetes or its exacerbation
(11)

.

On the other hand, some evidences available on which state that metformin is responsible to
accelerate the wound healing process. A timely and orderly M2 macrophage polarization is
helpful in wound healing process. An in-vitro study in rat skin defect models, where metformin
was used as a topical application, which improved wound healing and angiogenesis. This was
due to the bounded M2 macrophage polarization. Moreover, it was also found that the level of
relative proteins of NLRP3 inflammasome was markedly reduced by the metformin treatment
(12)

.

Therefore, this research was conducted to determine whether metformin have a protective or
harmful effect in the wound healing of DFU and also to assess the quality of life (QoL) of these
patients.

3

NEED FOR THE STUDY
DFUs are one of the major and debilitating issues of poorly controlled diabetes and causes of
non-traumatic lower extremities amputations worldwide. The foot-related complications of
diabetes are multifactorial in nature, they often rapidly progress into foot amputations
especially when foot ulcerations are involved. These complications if not managed properly
can cause partial or complete amputations of foot. A poor glycaemic control affects the healing
of the wound by delaying the healing time, hence it is essential to have an effective treatment
for a proper glycaemic control which thereby can encourage a proper healing mechanism (13).
Metformin is one of the oldest anti-diabetic medication used for the management of T2DM.
The drug acts by reducing the intestinal absorption and hepatic production of glucose and
besides promote peripheral glucose uptake (14). The drug’s beneficial action on circulating
lipids has been related to the decreased fatty liver. It activates the AMPK cascade in
hepatocytes, which in turn inhibits the mTOR thereby delays the healing mechanism (15).
Since metformin is the most frequently prescribed anti-diabetic medication, we framed a study
to assess the effect of metformin on the process of wound healing in the patients with DFU.
The purpose of the study was to determine if there is any significant relationship between
metformin treatment and the wound healing. Since the diabetic foot complications affect the
QoL of the patient to a great extent. It is already known these people have low self- reported
QoL and affects their physical as well as mental health. Therefore, we also focused on the effect
of DFU on QoL. We have evaluated their both physical and mental health status using a QoL
tool - Diabetic foot ulcer – short form scale (DFS- SF) developed by Mapi Research trust.
Additionally, we also studied the prescribing pattern in DFU patient, because which has great
impact on the final outcome of this disease condition.

4

AIMS & OBJECTIVES
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AIMS & OBJECTIVES
Aim:
•

To determine the effect of metformin on clinical outcome of DFU patients and to assess
the QoL of DFU patients

Primary objective:
•

To determine the effect of metformin on healing of wound in DFU patients.

Secondary objective:
•

To assess the HRQoL of DFU patients.

•

To study the general prescribing patterns for the management of DFU.

6

METHODOLOGY
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METHODOLOGY
Study Site: The study was carried out in the Department of Medicine and Department of
Surgery, Kasturba Hospital (KH), Manipal, a tertiary care hospital in South-India.

Study design: A prospective cohort study.

Study period: 7 months-period (August 2019 – February 2020)

Sample Size: 76 patients, presented with complaints of DFU and its complications, who
were prescribed any anti-diabetic agent in the Department of Surgery and Medicine at Kasturba
Hospital, Manipal during the study period were prospectively identified and recruited after
obtaining written informed consents.

Study criteria:
Inclusion criteria:
▪

Old and newly diagnosed DFU patients.

▪

Both gender

▪

Patients either on metformin or its combination or other anti- diabetic medications.

▪

Patients greater than age of 35 years

▪

Only T2DM patients with diabetic foot complications were included.

Exclusion Criteria:
▪

Patients not on any anti- diabetic medication

▪

Patients on any other medications which delay wound healing such as high dose
NSAIDS ex: ibuprofen, celecoxib, anti – rheumatoid agents ex: methotrexate.

Data source:
The study population broadly represents the South-Indian population. All relevant data was
obtained from the medical records of T2DM patients with foot ulcers who were admitted during
the study period. Baseline information such as age, sex, sugar profile, wound diameter, medical
and social history, quality of life scores and length of hospitalization were recorded from the
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inpatient and outpatient files. Data of post-discharge follow-up at 4 months were obtained from
out-patient records.

Study materials:
✓ Participant Information Sheet (PIS) - Used to provide necessary details (purpose,
benefits/risks, procedure) regarding the study.
✓ Informed Consent Form – An Informed consent form in Kannada or English was
obtained from each participant/ Legally Authorized Representative before study
initiation.
✓ Case Report Form (CRF) - To collect patient data (demographics, risk factors, treatment
regimen, lab data & other clinical investigations) [Appendix-V].
✓ Diabetic foot ulcer scale- short form (DFS SF) © 2015, (2nd edition, May 2015),
developed by Mapi Research Trust, in Kannada (16) or English- is a QoL questionnaire
tool given to the patients after prior permissions the trust [Appendix-VI c &d].

Operation modality:
▪ Ethical clearance was obtained from the Institutional Ethics Committee (IEC) of KH,
Manipal. (IEC No: 579/2019) [Appendix-I].
▪ A standard Case Report Form (CRF) was designed to record patient data
(demographics, risk factors, prescription, lab data & other clinical investigations)
[Appendix-V].

Methods:
Patients admitted with DFUs and its complications in the medicine and surgery department
were prospectively identified. Based on the inclusion criteria, participants were selected after
obtaining written informed consents from the patient or their legal representatives.
Participants were grouped into 2 cohorts: study cohort and reference cohort. Study cohort
included DFU patients who were receiving metformin or its combination along with other
drugs prescribed by the physician. Whereas, the reference cohort were patients with DFU
patients who were receiving any other anti-diabetic therapy but not metformin. Patients clinical
response was evaluated by measuring the wound diameter, healing time, sugar profile and
glycosylated haemoglobin (HbA1c).
9

Furthermore, each patients’ QoL was assessed using a health-related QoL questionnaireDiabetic foot ulcer scale- short form (DFS-SF) developed by the Mapi Research trust after
taking permission to use [Appendix VI a-d]. DFS-SF was administered during the patient’s
stay in the hospital. The quality of life scores obtained were categorized according to the
individual domains which were classified as 7 different domains as following: leisure, physical
health, dependency, daily life, negative emotions, worried about ulcers and person bothered by
ulcers. The scores were obtained on a scale of 0 – 5, 0 – not at all, 5 – a great deal. The scores
were calculated domain wise.
The scores were reverse – coded, hence every score was first reversed by subtracting the
individual score with the number 6, the score for each question in domain were summed and
subtracted by the least possible score of the domain. The particular domain score was calculated
by the formula: (sum of the domain scores – minimum possible domain score / range) * 100,
giving the individual domain score. The QoL scores of populations was compared, after
categorizing them on the basis of the gender, and calculating the means and standard deviations
of various domains.
Post discharge 2 follow ups were conducted: first one after 4 months from out-patient records
and the second one at the end of the study period.

Statistical methods:
Descriptive statistics was used with Statistical package for the social sciences (SPSS) version
25.0. Nominal data were expressed as frequency and percentage; and continuous variables were
by using descriptive statistics (mean ± Standard deviation). The independent sample t-test was
used to compute the variances and standard deviation between the duration of hospital stay
between teat and control groups. Association between use of metformin and wound healing
time were performed using Chi-square test. p< 0.05 was considered as statistically significant
for all the statistical analysis. Comparison of qualitative outcomes such as QoL scores were
also carried out by comparison of mean ± standard deviation, the reliability of questionnaire
scores was carried out by calculating Cronbach’s alpha.
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Figure 1: Study Flow Chart
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RESULTS

Patient demographics:
Out of the 76 patients with DFU (both old and newly diagnosed) that were admitted in the
hospital between August 2019 and February 2020 in Surgery and Medicine departments in
Kasturba Hospital, 64 (84%) were males and 12 (16%) were females as shown [Figure 2]. This
indicates that the incidence of DFUs is more in males than in females.

Figure 2: Gender-wise distribution of diabetic foot ulcer patients

12(16%)

64(84%)

Male

Female

13

Age-wise distribution of incidence of DFU
The age-wise distribution of the patients diagnosed with DFU is illustrated in Figure 3. The
age group most commonly affected by DFU were 40-60 years (40; 52.7%) followed by 60-80
years (33; 43.4%).

Figure 3: Age-wise distribution of diabetic foot ulcer patients
45
40

NO of DFU Patients

35
30
25
20
15
10
5
0
20-40

40-60

60-80

80-100

Age group

Duration of hospitalization
A comparison of the duration of hospitalisation shows no significant difference (t = - 2.87, p=
0.775) and the mean duration of hospitalization between reference cohort (Mean = 15.2 ± 9.23
days) and study cohort (Mean = 14.5 ± 10.76 days).
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mean days of hospitalization

16
15
14
13
12
11
10

Refrence cohort

Study cohort

Figure 4: Comparison of duration of hospitalization between the cohorts

Effect of metformin on wound healing of diabetic foot ulcer patients:
Association between metformin use and wound healing
The mean healing time of the study population is 2.37 ± 3.83 months, hence healing time was
categorized into < 3 months as well as ≥3 months. The mean healing time taken for the study
cohort is 3.0 ± 4.83 months and whereas, the mean healing time taken for the reference cohort
is 1.39 ± 1.28 months.
22 (50.0%) patients in study cohort have ≥3 months of healing time, whereas only 08 (25.0%)
of reference cohort have ≥3 months of healing time [Table 1]. This indicates that delay in
wound healing was higher in people on the metformin therapy compared people on other antidiabetic drugs.
Table 1: Association between metformin use and wound healing time
Healing time

Total

Statistical tests*

44 (100%)
32 (100%)
76 (100%)

X2 =4.846
p = 0.028

Cohorts

Study cohort
Reference cohort
Total

<3 months

≥3 months

22 (50.0%)
24 (75.0%)
46 (100%)

22 (50.0%)
08 (25.0%)
30(100%)

*Pearson’s Chi-square test; X2: Chi-square; p: Probability
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A statistically significant association was found in increased wound healing time between
patients on metformin treatment and patients with other anti-diabetic agents (X2 =4.846; p =
0.028).

Effect of metformin on amputation of diabetic foot ulcer patients:
Association between metformin use and amputation
31 (70.4 %) patients in study cohort have amputations, whereas only 15 (46.8%) of reference
cohort have amputation [Table 2]. This indicates incidence of amputation was higher in people
on the metformin therapy compared people on other anti-diabetic drugs.

Table 2: Association between metformin use and amputation
Amputation

Total

Statistical tests*

44 (100%)
32 (100%)
76 (100%)

X2 =4.31
p = 0.038

Cohorts

Study cohort
Reference cohort
Total

Yes

No

31 (70.4%)
15 (46.8%)
46 (100%)

13 (29.6%)
17 (53.2%)
30 (100%)

*Pearson’s Chi-square test; X2: Chi-square; p: Probability

A statistically significant association was found in increased incidence of amputation
between patients on metformin treatment and patients with other anti-diabetic agents (X2
=4.31; p = 0.038).
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Quality of life outcomes
The QoL was determined by employing a questionnaire - Diabetic foot scale – short form (DFS
SF) © 2015, (2nd edition, May 2015), developed by Mapi Research Trust.
The inter- method reliability of the questionnaire was determined to ensure the consistency of
the test scores, by calculating the Cronbach’s alpha, which was 0.847. A reliability scores
greater than 0.7 indicates the scores of questionnaires is consistent (17).
Various QoL domains shown below compares between male and female population. The
physical domains include leisure, physical health, dependency and daily life. The psychological
domains like negative emotions, worried about ulcers and bothered by ulcers.

Figure 5: Quality of life – Leisure sub-domain between the gender
80
70

Mean scores

60
50
40
30
20
10
male

female

Leisure sub-domain means score for male is 59.6 ± 3.39 (±SD), whereas for female 67.5 ± 7.78
(±SD) [Figure 5]. This shows that female DFU patients had a better leisure sub-domain
compared to the male DFU patients.
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Figure 6: Quality of life – Physical health sub-domain between the gender
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Physical health sub-domain means score for male is 61.3 ± 3.30 (±SD), whereas for female
55.8 ± 7.42 (±SD) [Figure 6]. This shows that male DFU patients had a better physical health
sub-domain compared to the female DFU patients.
Figure 7: Quality of life – Dependency sub-domain between the gender
80
70

Mean Scores

60
50
40
30
20
10
0
male

female

Dependency sub-domain means score for male is 56.7 ± 3.54 (±SD), whereas for female 65.1
± 7.12 (±SD) [Figure 7]. This shows that female DFU patients had a better dependency subdomain compared to the male DFU patients.
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Figure 8: Quality of life – Daily life sub-domain between the gender
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Daily life sub-domain means score for male is 60.2 ± 4.02 (±SD), whereas for female 69.8 ±
8.52 (±SD) [Figure 8]. This shows that female DFU patients had a better daily life sub-domain
compared to the male DFU patients.
Figure 9: Quality of life – Negative emotion sub-domain between the gender
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Negative emotions sub-domain means score for male is 57.6 ± 2.66 (±SD), whereas for female
48.6 ± 6.57 (±SD) [Figure 9]. This shows that female DFU patients had a better daily life
regarding negative emotions sub-domain compared to the male DFU patients.
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Figure 10: Quality of life – Worried about ulcers sub-domain between the gender
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Worried about ulcers sub-domain means score for male is 70.8 ± 3.57 (±SD), whereas for
female 61.5 ± 7.17 (±SD) [Figure 10]. This shows that female DFU patients had a better daily
life regarding worried about ulcer sub-domain compared to the male DFU patients.

Figure 11: Quality of life – Bothered by ulcer sub-domain between the gender
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Bothered by ulcer sub-domain means score for male is 61.9 ± 2.87 (±SD), whereas for female
63.2 ± 6.76 (±SD) [Figure 11]. This shows that male DFU patients had a better daily life
regarding bothered by ulcer sub-domain compared to the female DFU patients.
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Prescribing patterns in diabetic foot ulcer patients:
The prescribing patterns were analysed for the DFU patients, by collecting the data of 76
patients who were admitted in Kasturba Hospital, Manipal, during August 2019 - February
2020. The anti-diabetic and antibiotic drugs prescribed were included for evaluation [Table 3
&4].

Table 3: Prescription patterns for anti - diabetic agents in both cohorts
Anti -diabetics Class

Study Cohort
(n = 44 = 100%)

Reference Cohort
(n = 32 = 100%)

Biguanides

44 (100%)

0 (0%)

Insulin

32 (72.7%)

32 (100%)

Sulfonylureas

14 (31.8%)

2 (6.25%)

Dipeptidyl peptidase - 4 inhibitors

7 (15.9%)

2 (6.25%)

α -glucosidase inhibitors

2 (4.54%)

0 (0%)

Thiazolidinedione

1 (2.27%)

0 (0%)

Among 76 patients, the highest prescribed anti–diabetic agent was insulin (84.2%) followed by
biguanides (57.8%). 72.7% of the study cohort patients received insulin, whereas 100% of the
reference cohort received insulin
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Table 4: Prescription patterns for antibiotics in both cohorts
Antibiotic class

Study Cohort
(n = 44)

Reference Cohort
(n = 32)

Penicillins

23 (52.3%)

23 (71.8%)

Cephalosporins

3 (6.81%)

5 (15.6%)

Aminoglycosides

0 (0.00%)

1 (3.12%)

Sulpha drugs

1 (2.27%)

2 (6.25%)

Fluoroquinolones

8 (18.1%)

9 (28.1%)

Miscellaneous

12 (27.2%)

7 (21.8%)

3 (6.81%)

6 (18.7%)

(clindamycin, linezolid, meropenem)

Anti-Protozoal (tinidazole)

The penicillin was the commonly prescribed antibiotic class in study cohort (52.3%) and
reference cohort (71.8%).
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DISCUSSION
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DISCUSSION
A prospective cohort study was performed in Kasturba hospital, Manipal for 7 months (August
2019 to February 2020). This study comprises 76 patients admitted with diagnosis of DFUs.
Informed consent was obtained from the patients or legally authorized representative
(unresponsive patients) and data was collected from the medical records of the patients in
Surgery and Medicine departments.
A meta-analysis Zhang P, et al (18) reported that the prevalence of the DFUs globally was 6.3%,
in this male have 4.5% and in females 3.5%. They also found that the higher incidence was in
patients with T2DM (6.4%) than in patients with T1DM (5.5%). In our study, out of 76 patients,
64 (84%) were male and 12 (16%) were female. The incidence of DFU was more in men more
than in women.
Previous studies have reported that along with metformin, age also contributes to the delay in
wound healing (19). It is a known fact that the wound healing slows down with increasing age,
however the causal mechanisms involved are not clearly known. Although one of the theories
suggest that the possible mechanism may be due to the impairment in the vaso-regulation of
microcirculation of aged skin leading to the changes the inflammatory responses. This will in
turn decrease the production of progenitor cells and the circulatory mediators. This results in
the impaired temperature regulation and greater likelihood of hypoperfusion inhibiting the
wound to reach angiogenic stage. In our study, the age group 41-60 years were majorly (52.7%)
affected by the DFUs. De-ranged sugar levels cause a delay in the wound healing process,
although that is one of the prime factors, there are many other factors contribute to the improper
healing which may lead to the amputation of the foot.
A retrospective descriptive study conducted by Jansen et al (20) states that the median healing
time is six months (61.3%) in 1999 and 2000, whereas 6.6 months (67.8%) in 2011 and 2012
(p=0.02). Around 33% ulcers were healed, 17% underwent minor or major amputations and
1.5% were dies within a year after 1999. Similarly, around 30% ulcers were healed (p =0.06),
14% underwent amputations (p=0.02) and 12.8% were died within a year after 2011 and 2012
(p < 0.001). The presence of the infection was the only factor found significantly associated
with longer duration of ulcer.
Similarly, Ghosh et al

(1)

reports from the 62 million diabetic patients in 2017, about 25%

developed the DFUs, of which around 50% developed infection with a need of hospitalisation
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while 20% needed amputations. Annually, DFU contributes around 80% of all non-traumatic
amputations. The expected number of patients with diabetes will be raised to 134 million by
2045(21). Diabetes was found to have significant association with mortality and morbidity which
increased the burden on healthcare cost and reduced QoL.
Ochoa – Gonzalez, et al

(11)

found, apart from infection, metformin also contributes to the

wound healing delay processes. They conducted a prospective observational study for
analysing the ulcer area and size between 2 treatment groups (metformin and other antidiabetics) and found significant differences between 2 groups (p<0.05). The findings suggest
a decreased proliferation was present in the subjects treated with metformin and therefore,
ulcers with larger diameters were seen in the patients. We observed a significant association
between metformin and wound healing process (Χ2 = 4.846; p=0.028), indicating that
metformin causes delay in the wound healing process when compared to other treatment
options including the insulin therapy.
The delay in wound healing often leads to more serious complications like development of
gangrene. Gangrene is a serious condition where the body part starts decaying, due to severe
deprivation of nutrients and oxygen to the part of the body, this often leads to amputations of
the affected areas

(22).

The gangrene is further classified, into dry gangrene (presence of

ischemic tissue without infection) and wet gangrene (presence of necrotic tissues with
infection). The wet gangrene is often regarded as limb and life threatening, increasing the risk
of amputation in these patients (23). The infections often lead to foot amputations. We observed
a significant association between metformin and amputations (Χ2 = 4.31; p=0.038), suggesting
that metformin leads to delayed wound healing, thereby increasing the risk of infection. This
attributes to the increased amputations of lower extremities, when compared to other treatment
options including the insulin therapy. We also found that 13 (17.1%) out of the 76 patients
developed the foot gangrene. Of these, 11 (84.6%) patients were males and only 2 (15.4%)
were females. The type of gangrene showed that 10 (76.9%) patients had dry gangrene and 3
(23.1%) had developed wet gangrene with maggots’ presence.
Diabetes is associated with various complications, which leads to compromised QoL. The
health-related quality of life (HRQoL) are indicators of patients’ estimate of their health at that
time. There are different methods of assessing the QoL in patients including surveys, quality
of well-being (QWB) scale, sickness impact profile (SIP), etc.
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The QoL of the patients were assessed using a validated questionnaire - Diabetic foot scale –
short form (DFS SF). This was translated into Kannada. (16)
The questionnaire’s inter- method reliability was assessed to ensure the consistency of the test
scores, by calculating the Cronbach’s alpha which came as 0.847. Normally, a reliability scores
greater than 0.7 indicates the scores of questionnaires to be consistent. (17)
The means scores of various domains between the males and females were compared. These
were observed that the men had better QoL scores in the physical domains of physical health
(61.3 ± 3.30), dependency (56.7 ± 3.54) and bothered by ulcers (61.9 ± 2.87), whereas women
had better mean scores in the domains of leisure (67.5 ± 7.78) , daily life (69.8 ± 8.52) and
psychological domains of negative emotions (48.6 ± 6.57) and worried by ulcers (61.5 ± 7.17).
In an acute presentation of DFI, the identification of causative organism is a time-taking
process. Therefore, influences the framing of the suitable empirical antibiotic therapy. A
prospective observational study by Pillai et al (24) in Chitradurga, India for a study period lasting
for 6 months was carried out to investigate the prevalence as well as prescription patterns of
DFU patients along the use of anti- microbial agents, only 35(23.3%) were diagnosed with
DFU. Among this 26 were males and 9 were females. They found these patients were
prescribed with metformin (44.9%), followed by short and intermediates acting insulin (40.2%)
and sulfonylureas (36.2%).
Our study also evaluated prescribing patterns of the anti-diabetic and antibiotic prescriptions.
It was found that among the different antidiabetic classes of drugs the highest prescribed agent
was insulin (84.2%), biguanides (57.8%), followed by sulfonylureas (21.0%).

Largely

prescribed drug was biguanides (100%), followed by insulin (72.7%) and sulfonylureas
(31.8%) in the study cohort. Similarly, insulin (100%), followed by sulfonyl ureas (6.25%)
were in the reference cohort, in addition to dipeptidyl peptidase - 4 inhibitors (6.25%).
A prospective study was conducted by Ramadi P (25), to analyse the antimicrobials prescription
patterns in DFU patients in a hospital with tertiary care facility in South India. 80 DFU patients
were studied with mean age of 45.6 years, showed that ceftriaxone as well as metronidazole
were the most commonly prescribed empirical therapy to the DFU patients. Whereas, in our
study, β- lactam antibiotics like penicillin (52.3%) were found to be the most commonly
prescribed drug followed by miscellaneous drugs like clindamycin (20.5%) and linezolid
(6.81%) in study cohort. Meanwhile, fluoroquinolones (28.1%) and miscellaneous drugs
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(21.8%) like clindamycin (21.05%) and anti-protozoal such as tinidazole (18.7%) were highly
prescribed in the reference cohort.
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LIMITATIONS
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LIMITATIONS
•

The sample size of the study was relatively small, therefore, there is a limitation to
generalize the results.

•

Impact of metformin therapy on QoL was not able to perform due to follow-up of
the patients at the out-patient departments.

•

Since the study is performed at single center, the generalizing the result to other
population may not be pragmatic.

•

Complete social history assessment was difficult due to the social stigma associated
with smoking and alcohol consumption.

•

We were not able to adjust all the cofounding factors that affect the mechanism of
healing of wound.
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CONCLUSION
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CONCLUSION

The study reports a significant delay in healing of wound in the DFU patients who were on
metformin therapy comparing to those who were on other antidiabetic drugs. In addition to
this, the patients on metformin have increased incidence of amputations. Apart from the
metformin, deranged sugar profile also may attribute to increased amputations the population.
The QoL is also altered in the DFU patients, suggesting the increased disease burden on the
patient and patient party. Hence, it become important to educate the patients regarding the
pros and cons of the metformin therapy before initiating. Additionally, make them understand
the importance of maintaining proper sugar levels to avoid the complications of diabetes.

31

FUTURE DIRECTIONS
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FUTURE DIRECTIONS
• A comparative study of metformin with nuclear factor-E2-related factor (NRF2) to
determine the effect on healing of wound in patients with DFU. (26)
•

A multicentric randomized control study should be conducted to determine the
effectiveness of metformin on healing of wound in DFU, which will help to generalize the
data to wider population.

•

Pharmacoeconomic and quality of life study should be carried out to determine effect of
the metformin on humanistic and economic outcomes.
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Appendix II a: Participant Information Sheet (English)
Project title: To study the effect of metformin in wound healing in diabetic foot ulcer patients.
IEC No.: 579/2019
Sponsor Name: NA
Language: English

Principal Investigator: Manyasreeprapti.Rao. Y
Designation: 5th year PharmD student
Hospital: Kasturba hospital
Mobile number: + 91 8108633633
Please read this form carefully. If you don’t understand the language or any information in
this document, please discuss with study doctor. Your participation in this study is voluntary,
and you can enquire about all details before giving your written consent to participate in this
study.

1. Introduction to the research study:
You are invited to participate in this study because you have DIABETIC FOOT ULCER and
are on metformin. This study involves the effect of metformin in wound healing. This is an
observational study and no changes will be done in your treatment.
2. Purpose of the study:
To study the effect of metformin in wound healing in diabetic foot ulcer patients.
3. Who can take part:
•
•

Inclusion Criteria: Old and newly diagnosed diabetic foot ulcers patients, either on
metformin or its combination or other anti- diabetic medication.
Exclusion Criteria: Patients not on any anti- diabetic medication.

4. Information about the study (as a whole):
•
•
•
•
•
•

All about 200 patients (including the test and control groups) are expected to participate in the
study conducted between September 2019 and March 2020.
This is an observational study.
The patients will be divided into 2 different groups, one will be the test group including new or old
diabetic foot ulcer patients on the metformin or its combination therapy, whereas the control group
would be those who receive other anti-diabetic drugs except metformin.
Metformin dose: As per the doctor’s prescription.
The wound characteristics will be studied on periodically for assessing the wound healing process.
Patients’ quality of life will be assessed on basis of a quality of life questionnaire provided.
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5. What will happen to you (the individual participant) during the study:
• Don’t miss any follow up session planned by the physician.
• At the end of each visit we would take the information on your wound characteristics and your
sugar profile.
• Your regular laboratory details will be taken and the wound diameter will be measured.
• You will be given the dfs- sf 36 qol questionnaire distributed by the Mapi Research Trust
and response will be taken.
6. Your (the individual participant) role/responsibility in the study:
•
•
•
•

Provide accurate information whenever asked.
Inform the study doctor about any problem/side effects experienced during the study.
Follow the investigators instruction.
If you want to discontinue from the study, study doctor to be informed.

7. What are the risks?
• Minimal risk is involved, since the study is observational in nature.
8. What are the potential benefits of participating in the study:
You may or may not get benefit from participating in this study. It is possible that you may
get better, stay the same, or get worse. If you take part in this study you may help other
patients with diabetic foot infection contributing to the knowledge on management of the
disease.
9. What are the alternative treatments available:
If you decide not to participate in this study, there will be no change in your current standard
of care.
10. Cost of participating in the study:
No additional cost will be burdened on you (patient).
11. Compensation for injury:
If a medical problem arises during this research study as a direct result of the study treatment,
the study doctor will be responsible for making sure that proper medical care is provided to
you.
.
12. Confidentiality of information:
Information from the study records including your name, address, medical records, results of
tests, study results will be kept confidential and will be reviewed only by authorized
personnel from the investigators, Ethics Committee or regulatory bodies. The data will not be
made available to another individual unless you specifically give permission in writing.
Information and results from this study may be presented at meetings or published in journals
without including your name and personal identifications. No reference will be made in oral
or written reports which could link you to the study.
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13. New information about the study:
Any new information available during the course of the study will be informed to you if it has
relevance to your decision regarding continuing in the study. Results of your participation
will be disclosed to you if you indicate your desire for it.
14. Voluntary participation:
Your participation in this study is voluntary; you may decline to participate at any time and
you need not give any reason for the same, and such withdrawal shall be without penalty and
without loss of benefits to which you are otherwise entitled. If you withdraw from the study
prior to its completion, you will receive the usual standard of care for your disease, and your
non participation will not have any adverse effects on your subsequent medical treatment or
relationship with the treating physician.
If you withdraw from the study before data collection is completed, your data collected until
you indicated withdrawal will be used in the study report. Sponsor or the investigator may
stop the research or your participation in it at any time for some or other reason without your
permission.
15. Whom to contact in case of any questions:
If you experience adverse effects as a result of participating in this study, you may contact the
Principal Investigator Yendamuri. Manyasreeprapti.Rao as detailed above.
If you have any questions about the informed consent process or your rights as a participant,
you may contact the Member Secretary of the Kasturba Medical College and Kasturba
Hospital - Institutional Ethics Committee at Room 22, Ground floor, KMC Faculty Rooms,
adjacent to KMC Administrative Block, Kasturba Medical College, Manipal - 576104.
Phone: 0820 29 33522. Timings: 9: 00 AM to 5: 00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name: Dr. Rajesh.V
Address: Assistant Professor (Selection Grade)
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences, MAHE, Manipal.
Telephone No: + 91 9538417313
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Appendix II b: Participant Information Sheet (Kannada)
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Appendix III a: Informed Consent Form (English)
INFORMED CONSENT FORM

Project title: To study the effect of metformin in wound healing in diabetic foot ulcer patients.
I confirm I have read the Participant Information Sheet for the above study and its contents were
explained and I have had the opportunity to ask questions and received satisfactory answers.
I understand that my participation in the study is voluntary and that I have the right to withdraw at
any time without giving any reason, without my medical care or legal rights being affected.
I agree to take part in the above study. I confirm that I have received a copy of the Participant
Information Sheet along with this signed and dated informed consent form.
Name of the Research Participant:
Age of the Research Participant:
Address of the Research Participant:
Occupation:
Annual Income of the Participant:
Name & address of the nominee(s) and his relation to the Participant:

_________________________________________________________________________

__________________________
Signature of the research subject

_________
Date

__________________________

_________

Name & Signature of the witness

Date

_______________________________________________
Name & Signature of the person explaining the consent

_________
Date
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Appendix III b: Informed Consent Form (Kannada)
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Appendix IV a: Patient information sheet + informed consent for
questionnaire
PARTICIPANT INFORMATION SHEET
Protocol title: To study the effect of metformin in wound healing in diabetic foot ulcer patients.
Protocol No.: IEC:
Principal Investigator: Manyasreeprapti.Rao. Y
Designation: 5th year PharmD student
Contact number: +91 8108633633

Please read this form carefully. If you decide to volunteer to take part in this study you must sign the
informed consent document below.
This study assesses the quality of life of diabetic foot patients using Diabetic foot ulcer scale – short
form (DFS-SF) quality of life questionnaire. A validated questionnaire will be given to you to assess
your quality of life as you are having diabetic foot ulcer.
There are 5 questions with following sub questions in 5 pages. The time required to answer these
questions is approximately 20 minutes.
Entering a research study is voluntary. You may decline participation without giving any reason. Your
participation in this research will not bestow upon you any competitive academic or occupational
advantage over other students or staff who do not volunteer, and we will not impose any academic
or occupational penalty on those students or staff who do not volunteer
If you have any questions about this form or any study related issue, you may contact the Principal
Investigator as above.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

INFORMED CONSENT
Protocol title: To study the effect of metformin in wound healing in diabetic foot ulcer patients.

I understand that my participation in this questionnaire-based study is voluntary and I can decline
participation without giving any reason. I have been given sufficient opportunity to ask questions and
received satisfactory answers. I understand that I am allowed to take a photograph of this signed and
dated informed consent form as my reference copy.
Name of the research participant: _______________________________________
Signature of the research participant: _____________________________________
Date: ______________
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Appendix IV b: Patient information sheet + informed consent for
questionnaire (Kannada)
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Appendix V: Case Report Form
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Appendix VI a: Diabetic foot scale – short form questionnaire
(Licence)
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Appendix VI b: Diabetic foot scale – short form questionnaire
(Addendum for translation)
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Appendix VI c: Diabetic foot scale – short form questionnaire
(English)
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Appendix VI d: Diabetic foot scale – short form questionnaire
(Kannada)
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